Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Accumulated Expenses (2016 - 2025)

International Stem Cell (ISCO) has disclosed Accumulated Expenses for 16 consecutive years, with $452000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses fell 4.84% to $452000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $452000.0, a 4.84% decrease, with the full-year FY2024 number at $527000.0, up 8.66% from a year prior.
  • Accumulated Expenses was $452000.0 for Q3 2025 at International Stem Cell, down from $651000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $651000.0 in Q2 2025 to a low of $284000.0 in Q3 2021.
  • A 5-year average of $510578.9 and a median of $508000.0 in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: fell 24.06% in 2021, then surged 67.25% in 2022.
  • International Stem Cell's Accumulated Expenses stood at $404000.0 in 2021, then increased by 25.74% to $508000.0 in 2022, then fell by 4.53% to $485000.0 in 2023, then increased by 8.66% to $527000.0 in 2024, then decreased by 14.23% to $452000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Accumulated Expenses are $452000.0 (Q3 2025), $651000.0 (Q2 2025), and $608000.0 (Q1 2025).